Aurisco Pharmaceutical Co.,Ltd.

SHSE:605116 Lagerbericht

Marktkapitalisierung: CN¥9.0b

Aurisco PharmaceuticalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Aurisco PharmaceuticalLtd is forecast to grow earnings and revenue by 27.4% and 23% per annum respectively. EPS is expected to grow by 27.4% per annum. Return on equity is forecast to be 19.6% in 3 years.

Wichtige Informationen

27.4%

Wachstumsrate der Gewinne

27.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum19.3%
Wachstumsrate der Einnahmen23.0%
Zukünftige Eigenkapitalrendite19.6%
Analystenabdeckung

Low

Zuletzt aktualisiert07 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?

Sep 19
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?

Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?

Aug 14
Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?

Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings

Jun 28
Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings

Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet

Jun 07
Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet

Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings

May 12
Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings

Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today

Apr 22
Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today

Gewinn- und Umsatzwachstumsprognosen

SHSE:605116 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20262,436638N/A5903
12/31/20252,033523N/A4723
12/31/20241,627395N/A3603
9/30/20241,428341-151398N/A
6/30/20241,441382-46405N/A
3/31/20241,296326-9395N/A
12/31/20231,26328980386N/A
9/30/20231,16225780367N/A
6/30/20231,0521909242N/A
3/31/20231,09121614221N/A
12/31/20221,008211-50166N/A
9/30/2022983222-122130N/A
6/30/2022911202-82185N/A
3/31/2022836177-52203N/A
12/31/2021803169-49202N/A
9/30/2021767151-15171N/A
6/30/2021741137-10172N/A
3/31/202172714034220N/A
12/31/202072115756214N/A
9/30/2020688206143255N/A
12/31/2019582186107180N/A
12/31/201857513716110N/A
12/31/201754445N/A118N/A
12/31/201659087N/A188N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 605116's forecast earnings growth (27.4% per year) is above the savings rate (2.9%).

Ertrag vs. Markt: 605116's earnings (27.4% per year) are forecast to grow faster than the CN market (25.8% per year).

Hohe Wachstumserträge: 605116's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: 605116's revenue (23% per year) is forecast to grow faster than the CN market (14% per year).

Hohe Wachstumseinnahmen: 605116's revenue (23% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 605116's Return on Equity is forecast to be low in 3 years time (19.6%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y